News & Events
- Overview
- Stock Information
- News & Events
- SEC Filings
- Analyst Coverage
- Corporate Governance
- Shareholder Services
- Corporate Presentation
-
Feb 17, 2021Conference call scheduled for 4:30 p.m. ET today
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
-
Feb 10, 2021Conference Call Scheduled for Wednesday, February 17 at 4:30 p.m. Eastern Time
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...
-
Jan 6, 2021Greg Zante Promoted to Chief Financial Officer and Marianne Mancini Promoted to Chief Operating Officer
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
-
Jan 5, 2021
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
-
Nov 10, 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...